{"id":"NCT02968004","sponsor":"OPKO Health, Inc.","briefTitle":"Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children","officialTitle":"A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2019-08","completion":"2024-05","firstPosted":"2016-11-18","resultsPosted":"2021-06-25","lastUpdate":"2025-07-20"},"enrollment":224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Growth Hormone Deficiency"],"interventions":[{"type":"DRUG","name":"MOD-4023","otherNames":["Somatrogon"]},{"type":"DRUG","name":"Somatropin","otherNames":["Genotropin"]}],"arms":[{"label":"MOD-4023","type":"EXPERIMENTAL"},{"label":"Genotropin","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.","primaryOutcome":{"measure":"Annual Height Velocity in Main Study Phase","timeFrame":"52 weeks","effectByArm":[{"arm":"MOD-4023","deltaMin":10.1,"sd":null},{"arm":"Genotropin","deltaMin":9.78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":81,"countries":["United States","Argentina","Australia","Belarus","Bulgaria","Canada","Colombia","Georgia","Greece","India","Israel","Mexico","New Zealand","Poland","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38717038","38053515","37955005","35405011"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":109},"commonTop":["Injection Site Pain","Nasopharyngitis","Headache","Pyrexia","Cough"]}}